Grifols, S.A. (BME:GRF)
Spain · Delayed Price · Currency is EUR 11.82
-0.29 (-2.36%)
Oct 17, 2025, 5:35 PM CET
Grifols Revenue
Grifols had revenue of 1.89 billion EUR in the quarter ending June 30, 2025, with 4.03% growth. This brings the company's revenue in the last twelve months to 7.45 billion, up 9.32% year-over-year. In the year 2024, Grifols had annual revenue of 7.21 billion with 9.41% growth.
Revenue (ttm)
7.45B
Revenue Growth
+9.32%
P/S Ratio
0.96
Revenue / Employee
312.41K
Employees
23,833
Market Cap
7.13B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.21B | 620.41M | 9.41% |
| Dec 31, 2023 | 6.59B | 528.01M | 8.71% |
| Jan 1, 2023 | 6.06B | 1.13B | 22.92% |
| Dec 31, 2021 | 4.93B | -406.92M | -7.62% |
| Dec 31, 2020 | 5.34B | 241.35M | 4.73% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Almirall | 1.05B |
| Laboratorios Farmaceuticos Rovi | 749.00M |
| Faes Farma | 543.77M |
| Laboratorio Reig Jofre | 336.87M |
| Clínica Baviera | 288.92M |
| Prim, S.A. | 240.68M |
| Atrys Health | 226.24M |
| Pharma Mar | 189.27M |
Grifols News
- 10 days ago - Spanish court summons Gotham City founder in Grifols share price probe - Reuters
- 13 days ago - My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha
- 17 days ago - Grifols: Significant Upside Likely Materializing - Seeking Alpha
- 5 weeks ago - Blood donors surprised Canadian plasma products being sold abroad - CBC News
- 2 months ago - Grifols S.A. declares $0.1404 dividend - Seeking Alpha
- 3 months ago - Grifols: Reassuring Evidence, Still On The Sidelines - Seeking Alpha
- 4 months ago - XL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation® technology - GlobeNewsWire
- 5 months ago - Mason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General Meeting - Business Wire